AGP Picks
View all

Biosynth adds IVD materials to support assay development and supply security

Nov. 16, 2026
By AI, Created 06:00 UTC, Nov 16, 2026, AGP -

Biosynth is broadening its diagnostic materials portfolio ahead of MEDICA 2026 in Germany, adding recombinant materials, alternatives to animal-derived reagents and tunable enzyme substrates. The expansion is aimed at helping IVD developers reduce variability, improve assay performance and secure more reliable supply.

Why it matters: - IVD developers face pressure to control lot-to-lot variability while keeping assays stable as programs move toward commercialization. - Biosynth’s expanded portfolio is built to give developers more sourcing options and more control over assay performance. - The company is positioning itself as a supplier of both materials and development support, not just individual components.

What happened: - Biosynth is expanding its diagnostic materials offering with new recombinant materials, alternatives to animal-derived reagents and tunable enzyme substrates. - The company will feature the portfolio at MEDICA 2026 at Booth 3D66 in Düsseldorf, Germany, from Nov. 16-19. - Biosynth is also marking its 60th anniversary at MEDICA 2026.

The details: - The lineup includes two hepatitis A virus IgM monoclonal antibodies designed as an alternative to native hepatitis A materials used in diagnostic applications. - The HAV antibodies are intended to provide a non-infectious option with lot-to-lot reproducibility, simpler regulatory handling and scalable supply for long-term manufacturing. - Recombinant materials in the portfolio include rubella virus-like particles, recombinant horseradish peroxidase, recombinant rheumatoid factor IgM and autoimmune antigens. - Biosynth says these recombinant materials can help reduce lot-to-lot variability and give developers greater control over material characteristics. - The portfolio also includes synthetic alternatives to traditional animal-derived reagents and materials for selected cell culture applications. - Biosynth says those alternatives give developers more sourcing options for technical and supply needs. - Modular enzyme substrates are designed to let developers adjust substrate characteristics to refine sensitivity, specificity and signal intensity. - The company says the materials and capabilities are designed to help customers manage material variability, explore sourcing alternatives and fine-tune assay performance. - Biosynth describes itself as a developer and supplier of critical raw materials and services for life sciences and diagnostics. - The company’s broader business covers critical raw materials, regulated inputs, intermediates and specialty research chemicals for pharmaceutical and biopharmaceutical companies, diagnostics and IVD developers, life science research, academia, and specialty and applied markets. - Biosynth says its products and custom solutions support customers from research and development through scale-up and commercial supply. - More information is available in Biosynth’s MEDICA 2026 announcement. - Biosynth also shares company updates on LinkedIn.

Between the lines: - The portfolio expansion addresses two recurring pain points in diagnostics: supply reliability and material consistency. - Biosynth is also signaling that assay development often requires cross-disciplinary input from biologics and specialty chemicals. - The announcement frames material selection as an early-stage design issue, not only a manufacturing concern.

What's next: - Biosynth will use MEDICA 2026 to discuss material selection, assay requirements, sourcing and scale-up with visitors. - The company is likely to lean on the expanded portfolio to show how it can support developers across the full assay lifecycle. - Biosynth will continue presenting the anniversary as part of its scientific and manufacturing track record.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

European Morning Report

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

European Morning Report

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.